Strides Pharma Recalls 90,000 Bottles of Children's Ibuprofen for Contamination

Nearly 90,000 bottles of Children’s Ibuprofen Oral Suspension have been recalled nationwide by manufacturer Strides Pharma Inc. after the company received complaints of a "foreign substance" in the product. The U.S. Food and Drug Administration enforcement report cites complaints of a "gel-like mass and black particles" within the medication. Consumers are urged to stop using the affected 4-fluid-ounce bottles immediately and check for specific lot numbers.

Key Takeaways:

Scope of Recall: Strides Pharma Inc. is recalling nearly 90,000 bottles of Children’s Ibuprofen Oral Suspension (100mg).
Contamination Issue: The recall follows complaints of a "gel-like mass and black particles" found in the product.
Product Details: The recall involves 4-fluid-ounce bottles sold across the United States.
Immediate Action: Consumers must stop using the medicine if it matches the affected lot numbers.
Identification: Recalled bottles have lot numbers 7261973A or 7261974A and expire on January 31, 2027.

FDA Reports Gel-Like Mass, Black Particles in Medicine

The voluntary recall was initiated after the manufacturer received direct consumer complaints about the contamination. The FDA’s public report classifies the issue as a "Class II" recall, indicating a situation where use of the product may cause temporary or medically reversible health consequences. The specific nature of the foreign material has not been disclosed beyond its physical description.

Nationwide Recall Targets Specific Lots with 2027 Expiration

The affected product is identified as Children’s Ibuprofen Oral Suspension, 100 mg per 5 mL, in a 4-fluid-ounce bottle. Only bottles bearing the lot numbers 7261973A and 7261974A are part of this action. These bottles have a relatively distant expiration date of January 31, 2027, suggesting they are recently manufactured and likely still on store shelves or in medicine cabinets.

Conclusion:

This significant recall highlights critical quality control concerns in over-the-counter children’s medication. Parents and caregivers should promptly check their medicine cabinets for the identified lot numbers and discontinue use. The FDA and the company will continue to monitor reports of adverse events, and consumers with questions should contact Strides Pharma Inc. directly or consult the FDA’s recall website for official updates.